Malaria Host Pathogen Interaction Center: Gene and exon transcript abundances of uninfected Macaca mulatta treated with pyrimethamine over 7 time points in a 100 day study (GSE58340). Macaca mulatta

The Malaria Host-Pathogen Interaction Center (MaHPIC) is an inter-disciplinary NIH systems biology contract that utilizes multiple omics types (omics, clinical, and mathematical models), to iteratively test and develop hypotheses related to the complex host-parasite dynamics in the course of malaria infections in non-human primates with the goal of better understanding human disease. These data and metadata were produced by MaHPIC in collaborations between Emory University, Georgia Institute of Technology, and The University of Georgia as part of the MaHPIC contract (NIAID Contract: # HHSN272201200031C). Curation and maintenance of these data and metadata are the responsibility of the MaHPIC. Mary Galinski [e-mail] (MaHPIC Program Director), Jessica Kissinger [e-mail] (MaHPIC Co-Program Director), Esmeralda Meyer [e-mail] - MaHPIC Project Manager. Overall design: The experimental design of this pyrimethamine administration experiment with Macaca mulatta was approved by the Emory University Institutional Animal Care and Use Committee (IACUC) and is as follows. Five naive males (RCs13, RWr13, RUn13, RZe13 and RTi13) approximately 2 years of age were injected intravenously with a preparation of Anopheles dirus salivary gland material and then profiled for clinical and omic measurements over the course of a 100-day experiment. Samples were generated and analyzed as part of a multi-omic approach to understanding the effects that the anti-malarial drug pyrimethamine has on immune physiology in rhesus macaques (M. mulatta). There was no infection with Plasmodium parasites during this study. Whole blood and bone marrow RNA-Seq and plasma have been obtained for seven time-points before, during and after three rounds of drug administration. Samples are from either whole blood or bone marrow specimen types. 5 individuals were sampled for each specimen type, 7 times each over the 100 day experiment. 5 individuals * 2 specimen types * 7 time points = 70 samples. Biological samples (Whole Blood or Bone Marrow) were collected at 7 time points during the 100 days. These correspond to: Time Point 1 = Day 0 (Baseline Sampling Point) Time Point 2 = Day 21 Time Point 3 = Day 27 Time Point 4 = Day 52 Time Point 5 = Day 59 Time Point 6 = Day 90 Time Point 7 = Day 98 Pyrimethamine was administered on Days 21, 52, 53, 54, 90, 91, and 92.

疟疾宿主-病原体互作中心（Malaria Host-Pathogen Interaction Center, MaHPIC）是美国国立卫生研究院（National Institutes of Health, NIH）下属的跨学科系统生物学合同项目，整合多组学（omics，涵盖组学分析、临床数据及数学模型）技术，迭代验证并构建与非人灵长类疟疾感染过程中复杂宿主-寄生虫动态相关的假说，以期更深入地解析人类疟疾疾病的致病机制。本数据集包含的原始数据与元数据由MaHPIC联合埃默里大学、佐治亚理工学院及佐治亚大学共同产出，隶属于MaHPIC合同项目（美国国立过敏和传染病研究所（National Institute of Allergy and Infectious Diseases, NIAID）合同编号：HHSN272201200031C），相关数据与元数据的整理及维护工作由MaHPIC负责。项目联系人信息如下：项目主任Mary Galinski，邮箱[e-mail]；联合项目主任Jessica Kissinger，邮箱[e-mail]；项目管理员Esmeralda Meyer，邮箱[e-mail]。

整体实验设计：本项针对恒河猴（Macaca mulatta）的乙胺嘧啶给药实验方案已通过埃默里大学实验动物护理与使用委员会（Institutional Animal Care and Use Committee, IACUC）审批，具体流程如下：选取5只约2岁龄的未感染雄性恒河猴（编号分别为RCs13、RWr13、RUn13、RZe13及RTi13），经静脉注射接种按蚊（Anopheles dirus）唾液腺组织制剂，随后在为期100天的实验周期内开展临床指标与组学特征检测。本研究采用多组学策略，旨在解析抗疟药物乙胺嘧啶对恒河猴免疫生理的影响，实验全程未感染疟原虫（Plasmodium）。

在三轮给药的前、中、后共7个时间点，分别采集全血、骨髓样本用于RNA测序（RNA-Seq）并获取血浆样本。样本类型分为全血与骨髓两类，每类样本类型均采集5只个体的样本，每只个体在100天实验周期内采样7次，总样本量为5（个体数）×2（样本类型）×7（时间点）=70份。

本次实验的7个采样时间点对应如下：时间点1为第0天（基线采样点）、时间点2为第21天、时间点3为第27天、时间点4为第52天、时间点5为第59天、时间点6为第90天、时间点7为第98天。乙胺嘧啶给药时间为第21、52、53、54、90、91及92天。